Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Net Margin (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Net Margin for 9 consecutive years, with 1148.73% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 106893.0% to 1148.73% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.73% through Dec 2025, down 6491.0% year-over-year, with the annual reading at 0.79% for FY2025, 6413.0% down from the prior year.
  • Net Margin hit 1148.73% in Q4 2025 for Protagonist Therapeutics, up from 834.87% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 1148.73% in Q4 2025 to a low of 4551.0% in Q2 2022.
  • Historically, Net Margin has averaged 442.13% across 5 years, with a median of 205.03% in 2022.
  • Biggest YoY gain for Net Margin was 136574bps in 2021; the steepest drop was -1065402bps in 2021.
  • Year by year, Net Margin stood at 1031.57% in 2021, then plummeted by -103bps to 30.46% in 2022, then surged by 997bps to 273.35% in 2023, then tumbled by -71bps to 79.8% in 2024, then skyrocketed by 1339bps to 1148.73% in 2025.
  • Business Quant data shows Net Margin for PTGX at 1148.73% in Q4 2025, 834.87% in Q3 2025, and 626.96% in Q2 2025.